Richmond-based BioAge sees stock fall over 70% after halting obesity drug clinical trial
After a lucrative IPO in September, Richmond-based BioAge is seeing its biotech fortunes shift with its stock falling over 70 ...
BioAge shares tumble after decision to halt obesity drug study
The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...
BioAge Labs, Inc. (BIOA) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, ...
BioAge stock craters 70% on obesity drug study halt (update)
BioAge (BIOA) stock cratered 70% Friday evening after the company said it was discontinuing a Phase 2 study for its ...
FierceBiotech3d
BioAge's phase 2 obesity study derailed by liver side effects 2 months after IPO
It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...
BioAge halts ongoing Phase II trial of obesity drug due to liver concerns
In the trail, 11 participants in the azelaprag group exhibited transaminase elevations without significant symptoms.
BioSpace3d
BioAge Crashes After Axing Phase II Obesity Study
The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...
Levi & Korsinsky Reminds Shareholders of an Investigation into BioAge Labs, Inc. (BIOA) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, ...
Fintel on MSN3d
Citigroup Downgrades BioAge Labs (BIOA)
Fintel reports that on December 9, 2024, Citigroup downgraded their outlook for BioAge Labs (NasdaqGS:BIOA) from Buy to ...
BioAge Shares Slide Premarket After Obesity Study Halted for Safety
Shares of BioAge Labs plunged nearly 70% in premarket trading Monday after the clinical-stage biopharmaceutical company said it was ending a mid-stage study of its lead program, a proposed obesity ...
Seeking Alpha5d
BioAge stock craters 70% on obesity drug study halt (update)
Shares of BioAge (NASDAQ:BIOA) cratered 70% Friday in post-market trading after the company said it was discontinuing a Phase 2 study for its weight-loss drug azelaprag over safety concerns.
BioAge scraps mid-stage trial of experimental obesity drug
BioAge Labs said on Friday it is discontinuing the mid-stage trial of its experimental obesity drug after high levels of ...